Evidence map›Paper›PMID 30941722›Full record

Observational studyAdvances in therapy2019

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler

Jörgen Syk, Ines Vinge, Mikael Sörberg, Mikko Vahteristo, Paula Rytilä

Erratum issuedAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Advances in therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Today's improvement in asthma treatment: role of MART and Easyhaler.Multidisciplinary respiratory medicine · 2020
    Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jörgen SykDepartment of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Ines VingeAsthma-Allergy-Lung Department, Lidingö Hospital, Lidingö, Sweden.
Mikael SörbergOrion Pharma, Sollentuna, Sweden.
Mikko VahteristoOrion Corporation, Orion Pharma, Kuopio, Finland.
Paula RytiläOrion Corporation, Orion Pharma, Espoo, Finland. paula.rytila@orionpharma.com.ORCID http://orcid.org/0000-0002-9967-9134

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn real-life practice, asthma remains poorly controlled, with a considerable burden on patients' quality of life. Budesonide/formoterol (B/F) Easyhaler

methodsThe primary objective of this real-life, non-interventional, observational study was to show non-inferiority of asthma control when adult patients in Swedish primary care with persistent asthma switched from B/F Turbuhaler

resultsA total of 117 patients were enrolled in the on-treatment population; 81 (64.8%) were female. At visit 3, B/F Easyhaler

conclusionThis real-life, non-interventional, non-inferiority study in adults with persist asthma demonstrates equivalent or better disease control when patients switch from B/F Turbuhaler

fundingOrion Corporation, Orion Pharma.

Indexed as

Patient PreferenceAdministration, InhalationAdultAsthmaBronchodilator AgentsBudesonideBudesonide, Formoterol Fumarate Drug CombinationFemaleFormoterol FumarateHumansMaleMiddle AgedProspective StudiesSurveys and QuestionnairesTherapeutic EquivalencyTreatment OutcomeBronchodilator AgentsBudesonideBudesonide, Formoterol Fumarate Drug CombinationFormoterol FumarateAsthmaAsthma controlBudesonide/formoterol Easyhaler®Budesonide/formoterol Turbuhaler®Inhaler preferenceInhaler switchInhaler technique

Identifiers

PMID30941722
PMCPMC6824392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.